161 results about "Bone damage" patented technology

The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement.

Disclosed are a method and a corresponding pharmaceutical composition for treating damaged cartilage and subchondral bone. Neurogenic compounds in general and neuropeptides in particular have been found to be highly effective in stimulated repair of cartilage and bone damaged due to traumatic injury, ligament disease, and disuse. Preferred active ingredients for use in the method and corresponding pharmaceutical composition include calcitonin gene-related peptide (CGRP), cholecystokinin (CCK), dynorphin, enkephalin, galanin, neuropeptide Y (NPY), neurotensin, somatostatin, substance P (SP), thyrotropin-releasing hormone (TRH), vasoactive intestinal peptide (VIP).

A bone graft substitute using magnesium substituted calcium phosphate compounds and a method of manufacturing the same is provided in which the bone graft substitute is used for recovering bones damaged due to a bone fracture. The method of manufacturing a bone graft substitute includes the steps of mixing powdered calcium pyrophosphate and a magnesium included compound to thereby obtain a composition, pressure-forming the compositions to obtain a plastic body; and sintering the plastic body.

Provided are activated collagen scaffold materials as well as their special fused active restoration factors useful for promoting tissue repair, such as bone damage repair or nerve injury repair. The special fused active restoration factors are fusion proteins comprising a collagen-binding domain (CBD) at N- / C-terminus of cytokines, wherein the collagen-binding domain is a polypeptide consisting of 7-27 amino acid residues with a conservative sequence shown in SEQ IN NO:1 at N-terminus.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive impairment, decreased libido, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

A reamer for preparing a spinal upper facet to facilitate insertion of combined screw / washer implant, preventing bone damage and facet weakening, and also allowing possibility to place grafting so as to maximize implant stabilization. The reamer has shallow outer cutting surfaces to cut a groove for spike insertion; deep inner cutting surfaces to cut a cortical-penetrating bore for insertion of the screw, and a flat therebetween to limit penetration of these cutting surfaces.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

Disclosed is a method for forming carbonated calcium hydroxyapatite. The disclosed method can be used for forming bone cements or optionally cast, cured scaffolds such as may be used in many medical applications, including as implants for bone damage caused by, for instance, trauma, disease, or surgical excision due to disease. The cured materials include an interconnected network including both microporosity and macroporosity. The disclosed materials can be very similar in both chemical and physical make-up to natural bone mineral. The invention is also directed to systems that can be used for conveniently carrying out the disclosed methods.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

Compounds of structural formula (I) are disclosed as useful for modulating the androgen receptor (AR) in a tissue selective manner in a patient in need of such modulation, and in particular for antagonizing AR in the prostate of a male patient or in the uterus of a female patient and agonizing AR in bone and / or muscle tissue. These compounds are useful in the treating conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including: osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, arthritis and joint repair, alone or in combination with other active agents. In addition, these compounds are useful as pharmaceutical composition ingredients alone and in combination with other active agents.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

A bone graft substitute using magnesium substituted calcium phosphate compounds and a method of manufacturing the same is provided in which the bone graft substitute is used for recovering bones damaged due to a bone fracture. The method of manufacturing a bone graft substitute includes the steps of mixing powdered calcium pyrophosphate and a magnesium included compound to thereby obtain a composition, pressure-forming the compositions to obtain a plastic body; and sintering the plastic body.

The invention discloses a 3D print template for surgical puncture. The 3D print template comprises a template body and multiple columns with puncture holes; the columns are divided by seams penetrating through the puncture holes; outer rings are arranged on the outer sides of the columns; the template body is provided with locating rings. The invention further discloses a preparation method of the 3D print template for surgical puncture. By using the puncture template, the surgery time can be obviously shortened, and more importantly, the radiation exposure time of surgeons and patients can be obviously shortened; meanwhile, according to preoperative precise positioning, the puncture times can be reduced, the puncture angle is accurately determined, complications are avoided, and the curative effect is improved. Particularly, for patients suffering from congenital malformation and skeletal injury, the operation feasibility can be defined before an operation, and the puncture accuracy is improved.

The invention discloses an orthopedic nail removing device, which includes a bottom plate, Both sides of the top of the bottom plate are fixedly connected with bottom boxes, and the tops of the two bottom boxes are fixedly connected with horizontal boxes, the tops of the horizontal boxes are fixedly connected with top boxes, and sliding plates are slidably connected between opposite sides of the two bottom boxes, and the bottoms of the sliding plates are fixedly connected with motor boxes and fixed boxes, which relate to the technical field of medical instruments. As that orthopedic nail takedevice, through which the bottom of both moving plates penetrate and extend to the bottom of the stationary box, the screw which is corroded with the steel plate can be taken out smoothly, take out that steel plate, The screw can be fixed first, and then moved upward, and the screw is taken out slowly, so that the pain of the patient can be alleviated, the operation efficiency is improved, and thetime is saved. The invention has the advantages of simple operation, no need to increase the slot area, small bone damage surface, and effectively avoiding secondary injury to the patient.

The invention discloses an implant system based on titanium-zirconium alloys. The implant system comprises an implant, an artificial tooth base table and a center screw, two ends of the artificial tooth base table are provided with a dental crown connecting section and an implant inserting section respectively, the implant inserting section comprises a first frustum, a plum blossom-shaped column and a second frustum, the dental crown connecting section is connected with a large-diameter end of the first frustum, a small-diameter end of the first frustum is connected with one end of the plum blossom-shaped column, and the other end of the plum blossom-shaped column is connected with a large-diameter end of the second frustum. According to the implant system based on the titanium-zirconium alloys, the implant is of a double-threaded structure of a primary thread and a secondary thread, alveolar bone damage can be effectively reduced, generated cutting resistance is small, and the implant system effectively solves the problems of bone burn, stress concentration, micro-cracks of notching positions and the like.

The invention discloses a preparation method and an application of laponite (LAP) bioceramics. The method comprises a first step of tabletting LAP powder in a mold through a uniaxial pressing method to obtain LAP sheets; and a second step of sintering the LAP sheets in a muffle furnace to obtain the LAP bioceramics. The preparation method and application provided by the invention are simple in process; products are easily available; cost of LAP is relatively low; the prepared LAP bioceramics have good blood compatibility and good capacity for accelerating bone healing, and have wide application prospects in the fields of tissue engineering scaffold materials, particularly the field of bone damage repair.

Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, arthritic condition and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer s disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

The present invention relates to a process of using a heat responsive mixture to produce inorganic interconnected 3D open-cell bone substitutes which can be applied in the orthopedic or dental field for treatment of bone damage. The invention provides a simple and easily-controlled process of preparing porous inorganic bone substitute materials.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

The invention provides a medicament for treating bone damage and relates to a Chinese medicinal medicament for treating the bone damage, which is prepared from the following raw materials in part by weight: 20 to 28 parts of ground beetle, 55 to 65 parts of processed frankincense, 43 to 53 parts of processed myrrh, 25 to 35 parts of arisaema cum bile, 25 to 35 parts of dahurian angelica root, 25 to 35 parts of dragon's bones, 25 to 35 parts of processed nux vomica, 25 to 35 parts of largetrifoliolious bugbane rhizome, 14 to 22 parts of incised notopterygium rhizome, 14 to 22 parts of crab shell, 14 to 22 parts of grassleaf sweelflag rhizome, 25 to 35 parts of safflower, 25 to 35 parts of dragon's blood, 25 to 35 parts of divaricate saposhnikovia root, 20 to 28 parts of szechuan lovage rhizome and 14 to 22 parts of Chinese angelica. The medicament has the advantages that: clinical repeated practices prove that the medicament has the effects of quickening blood and dispelling stasis, dispersing swelling and relieving pain, soothing sinews and quickening blood, and dispelling wind and dissipating cold; and clinical repeated practices also prove that the medicament has high cure rate, concentrated medicinal strength, rapid action, no toxic or side effects, long duration of medicament effect, low cost, no pain of patients and wide application. The medicament also has the advantages of addressing of symptoms and root causes, quick response, safety, reliability and better curative effect. 278 clinical trials show that the total effective rate of the medicament reaches 96.4 percent.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer s disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

An exterior-applied Chinese medicine in the form of cream for treating bone injury is prepared from 6 Chinese-medicinal materials including acanthopanax bark, cinammon twigs, red sage root, egg, etc.

The present invention relates to applications of a bionic silicon-calcium hybrid collagen scaffold material within fiber, specifically to the osteoclastogenesis inhibition application of the bionic silicon-calcium hybrid collagen scaffold material within fiber, and the application of the bionic silicon-calcium hybrid collagen scaffold material within fiber as the bone defect repair material. According to the present invention, calcium ions and silicic acid released by the bionic silicon-calcium hybrid collagen scaffold material within fiber under the body fluid environment can promote osteogenic differentiation of the mesenchymal stem cells and induce the mesenchymal stem cells to secrete a large number of osteoprotegerin so as to provide effects of osteoclast activation inhibiting and bone damage function inhibiting, and in the late stage of implantation, the secretion of the osteoprotegerin returns to the normal level, and the activation of the osteoclasts is beneficial to the normal processing of the bone remodeling process.

Compounds of structural formula I as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and / or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporesis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, arthritis and joint repair, alone or in combination with other active agents.

Aqueous based tile etching solutions are disclosed containing hydrofluoric acid along with additives that can be used to reveal exposure. The exposure revealing additives of the present invention may have irritant properties so that an exposed individual can feel that skin contact has occurred and / or alternatively may dye the skin to reveal a colored or fluorescent stain where contact has taken place. The result is a hydrofluoric acid containing tile etching solution having improved overall safety by revealing when and where exposure has taken place. This becomes very important owing to the fact that skin contact with solutions containing hydrofluoric acid often go unnoticed for some time and may therefore result in substantial chemical injury including bone damage. The hydrofluoric acid employed in the present invention may be formed in situ by the interaction of a strong acid with a water soluble fluoride salt.